Research articles
ScienceAsia 48 (2022):ID 545-551 |doi:
10.2306/scienceasia1513-1874.2022.082
Isorhapontigenin improves the sensitivity of non-small cell
lung cancer cells to gefitinib by inactivation of the SP1/EGFR
pathway
Xingshu Wua, Zhixiang Sub, Xiaoping Rena,*
ABSTRACT: Non-small cell lung cancer (NSCLC) remains one of the most common cancers in the world. The aim
of this study was to explore the therapeutic potential of isorhapontigenin (ISO) to overcome gefitinib resistance in
NSCLC cells. Cell viability was higher in gefitinib-resistance A549 (A549/R) cells than that in A549 cells in response to
gefitinib. Combination of gefitinib and ISO enhanced the reduction in cell viability and cell colony number induced by
gefitinib or ISO alone. The number of apoptotic cells was increased in gefitinib and ISO combination group compared
with A549/R cells treated with gefitinib or ISO alone. Combination of gefitinib and ISO inhibited the repairment of
DNA damage in A549/R cells and repressed the activation of SP1/EGFR signaling pathway. In summary, data of this
study proved that ISO enhanced the sensitivity to gefitinib through inactivation of SP1/EGFR signaling pathway in
gefitinib-resistant NSCLC cells.
Download PDF
49 Downloads 1357 Views
| a |
Respiratory Department II, Shaanxi Provincial People?s Hospital, Shaanxi 710068 China |
| b |
Third Branch of Medicine, Shaanxi Cancer Hospital, Shaanxi 710061 China |
* Corresponding author, E-mail: renxiaoping10903@163.com
Received 2 Nov 2021, Accepted 18 Mar 2022
|
